Tag: Phase 2a
-

Teva’s TEV-‘408 Meets Phase 2a Primary Endpoint in Celiac Disease by Reducing Gluten-Induced Intestinal Damage
Teva’s anti-IL-15 antibody TEV-‘408 met the primary endpoint in a Phase 2a celiac disease study, significantly reducing gluten-induced intestinal damage and limiting intraepithelial lymphocyte expansion versus placebo.
-

Can Sionna Challenge Vertex’s Cystic Fibrosis Empire?
Sionna’s NBD1-stabilizing therapy could become the first credible challenge to Vertex’s dominant cystic fibrosis franchise.